Study to Investigate the Effectiveness of Different Single Oral Doses of BAY94-8862 on Natriuresis After Administration of 0.5 mg Fludrocortisone (Astonin H) With 50 mg Eplerenone (Inspra) as Active Control in Healthy Male Subjects in a Randomized, Single-blind, Placebo-controlled, Combined 3-fold Crossover and Parallel-group Design.

Trial Profile

Study to Investigate the Effectiveness of Different Single Oral Doses of BAY94-8862 on Natriuresis After Administration of 0.5 mg Fludrocortisone (Astonin H) With 50 mg Eplerenone (Inspra) as Active Control in Healthy Male Subjects in a Randomized, Single-blind, Placebo-controlled, Combined 3-fold Crossover and Parallel-group Design.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2015

At a glance

  • Drugs Finerenone (Primary) ; Eplerenone; Fludrocortisone
  • Indications Chronic heart failure
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Dec 2015 Trial focus has been changed from only Pharmacodynamics to both Pharmacokinetics/Pharmacodynamics.
    • 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
    • 22 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top